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In 1996, Batista reported a radical new surgical treatment for
dilated cardiomyopathy (1). It was based on the reduction of
left ventricular (LV) volume, resulting in a reduction in LV
wall stress, and a relative increase in LV wall thickness. This
innovative approach had the potential of providing an alterna-
tive to heart transplantation in the treatment of congestive
heart failure for non-ischemic dilated cardiomyopathy. As
other centers have adopted this procedure, data have accumu-
lated regarding its early mortality and the procedure’s effect on
intermediate term survival. The effect of the procedure on LV
performance is being studied, and the article in this issue by
Popovic et al. is a valuable report on early LV performance (2).
Relatively little is known about the long term effects of this
procedure on survival or on LV performance.
See page 1801
Early enthusiasm regarding this operation was somewhat
dimmed by a relatively high early mortality and the findings
that a significant number of patients required ventricular assist
devices or were relisted for transplantation. The early mortality
in the recent series has ranged from 2% to 22% (3–5). The one
year survival in Batista series of 120 patients was 55%; in the
series reported by McCarthy and associates it was 87%; and in
the series by Moreira and associates it was 59%. In McCarthy’s
series, 15% of patients required early LV assist devices and
28% were relisted for transplantation. These results are sober-
ing because survival for the medical treatment of nonischemic
dilated cardiomyopathy has been 81% at one year for patients
with an LVEDD of ,4cm/m2 and 65% for patients with an
LVED of .4cm/m2 (6). These results can also be compared
with those of heart transplantation. The early mortality for
nonurgent transplants is estimated to be 95%, and one year
survival is currently about 85% (7). Subsequent mortality is 4%
per year. The risk of dying while on the waiting list for heart
transplantation must be included, although with current opti-
mal medical therapy, the estimated one year risk of sudden
death for such patients is 8% (8). The overall mortality risk
while waiting is 20% (9). The survival benefit conferred by
transplantation is therefore seen in medium and long term
followup.
An important reason to explore options such as partial left
ventriculectomy (PLV) is the shortage of donor hearts and the
much greater number of patients in severe heart failure (10).
Other alternatives that must be compared to the PLV have
been proposed. These currently include cardiomyoplasty and
the use of a totally implantable left ventricular assist device.
Partial left ventriculectomy seems to have a far greater effect
on improving LV performance than cardiomyoplasty and is
performed on sicker patients. Cardiomyoplasty has not been
shown to have an effect on survival. Mechanical LV assist has
a reduced quality of life compared with these other options
because of the dependence on external power sources and a
noisy intra-abdominal device (11).
The PLV procedure is still in the early stages of its
development. Much is being learned about the selection of
patients, the conduct of the procedure and the postoperative
care. Popovic´ and associates have shown that patients with a
dominant right coronary artery have a better functional result
than those with a dominant circumflex, which is divided in the
procedure and causes distal ischemia. This is a valuable finding
and could result in improved selection or modification of the
procedure. Another factor, which this study has not addressed,
is the use of preoperative ultrafast computerized tomography
scans to evaluate segmental LV wall thickness. This may be
variable, and the resection of a thickened lateral wall, while
leaving a thinned out septum, could be expected to give a
suboptimal result. Intraoperative management may be crucial
to early and late outcomes. It seems that operating on the
beating heart, rather than using cardioplegia, gives better
results. In addition, the extent of resection may be critical. It is
interesting that in the series studied by Popovic´, three of the
patients required mitral valve replacement while 19 had mitral
valve repair. It is likely that in some patients, an adequate
resection cannot be performed without sacrificing the papillary
muscle, requiring mitral valve replacement.
The results of PLV must also be compared with those of
mitral valve repair. Early improvement in congestive heart
failure after correction of secondary mitral regurgitation in
end-stage cardiomyopathy has been reported in a small series
of patients by Bach and Bolling (12,13). They found improved
ejection fraction and reduced LV volume. All were improved
and there were no early deaths. Marked reduction in the mitral
valve annulus size may result in ventricular remodeling, as well
as improving the symptoms of heart failure due to mitral
regurgitation. This is an alternative option and may have a
lower early and late mortality compared with PLV.
Popovic´ et al.’s study adds to the accumulating evidence
that PLV does indeed accomplish its objectives of reducing LV
volume, improving ejection fraction and lowering LV filling
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pressures, thus effectively treating heart failure. The early
mortality thus far remains significant. In addition, the failure
rate reflected by recurrent symptoms and re-listing for trans-
plantation is unexpectedly high, and the one year survival may
be lower than medical therapy alone. It must be stressed,
however, that this is a relatively new operation. Improvements
in patient selection based on patient’s clinical status, underly-
ing cardiomyopathy, their coronary anatomy as shown by
Popovic´ et al., the LV wall thickness and the criteria not yet
defined will be developed in time. In addition, the intraoper-
ative management of these patients is evolving, and it is hoped
that it will yield a lower early and late mortality. Ultimately, a
randomized trial will be required to evaluate this procedure.
Meanwhile, this operation should be used on selected patients
in institutions that have active heart failure and heart trans-
plantation programs for the proper selection of patients and an
experienced cardiac assist device program.
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